DSM-TACE of HCC: Evaluation of Tumor Response in Patients Ineligible for Other Systemic or Loco-Regional Therapies.
Haubold J, Reinboldt MP, Wetter A, Li Y, Ludwig JM, Lange C, Wedemeyer H, Schotten C, Umutlu L, Theysohn J.
Haubold J, et al. Among authors: wetter a.
Rofo. 2020 Sep;192(9):862-869. doi: 10.1055/a-1111-9955. Epub 2020 Mar 4.
Rofo. 2020.
PMID: 32131109
Free article.
English.
KEY POINTS: . DSM-TACE is a safe treatment alternative for patients ineligible for other local or systemic treatments.. . ...Patients treated with DSM-TACE showed an overall good median survival of 682 days, strictly dependent on BCLC stage.. CITATION FORMAT: . Haubold J, …
KEY POINTS: . DSM-TACE is a safe treatment alternative for patients ineligible for other local or systemic treatments.. . ...Patients …